Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL6457513 | 0.87 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL28768643 | 0.85 | NAPRT (0.45) | NAPRTALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL21225256 | 0.85 | NAPRT (0.45) | NAPRTALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL318231 | 0.85 | NAPRT (0.45) | NAPRTALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL31249557 | 0.83 | NAPRT (0.43) | NAPRTALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL28970500 | 0.83 | NAPRT (0.43) | NAPRTALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL28907103 | 0.83 | NAPRT (0.43) | NAPRTALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL27984081 | 0.83 | NAPRT (0.43) | NAPRTALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL3991498 | 0.81 | ALDH1A1 (0.38) | NAPRTALDH1A1L3MBTL1 | |
| Pyrimidine SCHEMBL21056190 | 0.81 | NAPRT (0.42) | NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339706-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | claimed |
| US-6815447-B2 | 6-N-(2-AMINO-PYRIMIDIN-4-YL)QUINOLINE-6-AMINE DERIVATIVES; ANALGESICS | ASTRAZENECA AB (SE) | 2004-11-09 | — | — | US | claimed |
| US-20040058945-A1 | N-type calcium channel antagonists for the treatment of pain | CHAUDHARI BIPINCHANDRA (US) | 2004-03-25 | — | — | US | claimed |
| EP-1339706-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | claimed |
| WO-2002036586-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | claimed |
| EP-1339706-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-6815447-B2 | 6-N-(2-AMINO-PYRIMIDIN-4-YL)QUINOLINE-6-AMINE DERIVATIVES; ANALGESICS | ASTRAZENECA AB (SE) | 2004-11-09 | — | — | US | disclosed |
| US-20040058945-A1 | N-type calcium channel antagonists for the treatment of pain | CHAUDHARI BIPINCHANDRA (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1339706-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002036586-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| EP-0522038-A4 | SUBSTITUTED PYRIMIDINES, PYRIMIDINONES AND PYRIDOPYRIMIDINES | — | 1993-05-26 | — | — | EP | disclosed |
| EP-0522038-A1 | SUBSTITUTED PYRIMIDINES, PYRIMIDINONES AND PYRIDOPYRIMIDINES | MERCK & CO. INC. (US) | 1993-01-13 | — | — | EP | disclosed |
| US-5166206-A | Hypotensive agents, central nervous system disorders, glaucoma or angiotensin antagonist | MERCK & CO., INC. (US) | 1992-11-24 | — | — | US | disclosed |
| WO-1991015209-A1 | SUBSTITUTED PYRIMIDINES, PYRIMIDINONES AND PYRIDOPYRIMIDINES | MERCK & CO., INC. (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058945-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | NAPRT 933/4885ALDH1A1 3302/4885L3MBTL1 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.